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Spleen Tyrosine Kinase (Syk) is a 72 kDa non-receptor protein-tyrosine kinase. It 
plays an essential role in B cell development and signaling downstream of many immune 
receptors. However, its expression is not limited to just B cells, as it has been shown to 
play a functional role in signaling in many other hematopoietic cell types such as 
thymocytes, mast cells, macrophages and natural killer cells. Its expression and roles 
have expanded since its original discovery; and it has now been associated with epithelial 
tissues as well as tumor progression and prognosis. A particular interest has focused on 
Syk and its suggested tumor suppressor role in various epithelial-based carcinomas. Loss 
of Syk expression both at the mRNA and protein level in breast cancer has been 
associated with loss of cell-cell adherence and increased mobility and invasiveness. 
Similar effects have been observed with overexpression of protein arginine 
methyltransferase five (PRMT5) and seven (PRMT7) in breast cancer, indicating a new 
potential mechanism by which Syk may regulate the ability of cancer to metastasize. 
Western blot analysis has demonstrated Syk’s ability to alter the di-symmetric 
methylation of proteins catalyzed by PRMT5. PRMT5 and Syk were found to reside in a 
complex with one another. Further analysis by immunoprecipitation indicated that the 
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formation of this Syk-PRMT5 complex was dependent on nucleolin expression. A 
downstream substrate of PRMT5, SUPT5H, also displayed the ability to form a complex 
with Syk. SUPT5H is a component of a large complex that regulates mature B cell class 
switching. A component of this complex, LEO1, was also shown to interact with Syk 
through immunoprecipitation. These results suggest Syk interacts with the 
methyltransferase PRMT5 and some of its substrates. Furthermore, this study indicates 

























1.1 Syk Tyrosine Kinase  
 
Spleen Tyrosine Kinase (Syk) is a 72 kDa protein whose signal transduction 
function has been extensively studied in hematopoietic cells. Syk was originally isolated 
from bovine thymus (1). However, at that time it was only known to be a 40 kDa 
proteolytic fragment containing a catalytic domain (1-2). Later, antibodies generated 
against this fragment recognized a 72 kDa protein (2). In 1991, the first full length Syk 
cDNA was isolated from porcine spleen (3). Two years later research by the Clark lab led 
to the isolation of the full-length cDNA encoding the human homologue of Syk (4). 
Sequencing of the Syk cDNA revealed two tandem N-terminal Src-homology 2 (SH2) 
domains separated by a linker A region. The C-terminal catalytic domain is connected to 
the tandem SH2 domains via the linker B region (4). Many of Syk’s autophosphorylation 
sites can be found in these linker regions (5) (Figure 1.1).  
In the hematopoietic cell system, Syk plays a critical role in downstream signaling 
of immune receptors (6). For instance, following activation of the B cell antigen receptor 
(BCR), active lyn kinase will phosphorylate the tyrosine located on cytoplasmic tails of 
Igα (CD79a) and Igβ (CD79b) within the immunoreceptor tyrosine-based activation 
motif (ITAM) (7). These phosphorylated ITAMs then serve as docking sites for Syk 
through its tandem SH2 domains (6). This ITAM sequence can be found on numerous  






Figure 1.1 Schematic Diagram of Syk 
 
 
Syk contains two tandem SH2 domains that are separated by linker A. The kinase domain 
is separated from the SH2 domain by linker B. Depicted here are six autophosphorylation 
sites, among which Y130 has shown to effect ITAM binding and catalytic activity upon 
phosphorylation. Y342 and Y346 have been shown to be important for Syk interaction 
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other hematopoietic cell receptors such as the T-cell receptor (TCR), FcεRI receptors on 
mast cells, and activating receptors on natural killer cells (8,9). Upon docking to the 
ITAMs, Syk becomes activated where it can then autophosphorylate itself at tyrosine 
130, linker A region, and tyrosines 519 and 520 of the catalytic domain (10). Syk is also 
susceptible to phosphorylation by Lyn upon binding to the ITAM (10). This Lyn-based 
phosphorylation can occur at tyrosines 317, 342, and 346 of Syk’s linker B region, which 
are also susceptible to autophosphorylation. (10). Mutational studies of Tyr-130, 
replacing it with a glutamate, which mimics tyrosine phosphorylation, has a negative 
effect on Syk’s ability to interact with the ITAM while simultaneously enhancing its 
catalytic activity (11). A similar mutation of tyrosines 519 and 520 of the catalytic 
domain has shown autophosphorylation at these sites having no effect on the catalytic 
activity in vitro, but do affect Syk’s ability to signal in B cells (6,12,13). Tyrosine 317, 
whose phosphorylation is both Syk and Lyn dependent, is linked to a negative regulator 
of BCR Ca2+ signaling (14). Mutation of this site to a phenylalanine, mimicking a 
nonphosphorylated tyrosine, increased IP3 production and subsequent intracellular Ca2+ 
levels (14).  Interestingly, within that same Linker B region, phosphorylation of tyrosines 
342 and 346 acts as docking sites for the phospholipase C-γ (PLC-γ) SH2 domain, 
inducing its activation by Syk phosphorylation and downstream signaling leading to 
increased IP3 and intracellular Ca2+ levels (15,16). Multiple other proteins utilize these 
docking sites, such as Vav1. Vav1 uses the phosphorylated tyrosines 342 and 346 on Syk 
as a docking site for its SH2 domain, where it is then phosphorylated and activates its 
catalytic ability to exchange GDP for GTP on Rac-1 (17,18). 
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Syk can also be found in multiple other types of cells and tissue outside the 
hematopoietic cell lines. Such is the case for fibroblasts, where Syk played a repressive 
role in adipogenesis of the 3T3-L1 mouse embryonic fibroblasts (19).  Syk was also 
reported in neuronal cells including mouse brain cells PC12 and p19 and in many 
epithelial tissues. (20). Fluck et al. reported detecting Syk expression of multiple tumor 
breast tissue cell lines of epithelial origin such as SKBR and MCF-7 (21). Further 
investigation of Syk expression and breast tissues have demonstrated normal expression 
of Syk in human breast tissues and benign breast carcinoma tissue but undetectable levels 
of both Syk mRNA and protein in highly invasive breast cancer (22).  
 
1.2 Syk in Cancer 
 Various studies have reported Syk’s multifaceted role in cancer. It was found to 
have a tumor promoter role in hematopoietic cancers. For example, in B-cell lymphomas, 
Syk is constitutively active and is required for cell growth (23,24). Further evidence 
suggesting Syk’s prosurvival role was collected from clinical trials of fostamatinib, a 
selective Syk inhibitor. Patients with B-cell non-Hodgkin lymphoma and small 
lymphocytic leukemia/chronic lymphocytic leukemia saw tumor cell death upon 
treatment with this Syk inhibitor (25).  
 However, Syk has been shown to be a tumor suppressor in some epithelial-based 
carcinomas. Syk’s tumor suppressor role extends to various cancers including breast, 
gastric, pancreatic, cervical, and hepatocellular (22,26-29). Initial evidence of Syk’s 
tumor suppressor role was determined when Coopman et al. studied its expression levels 
in mammary epithelial cells (22).  Their finding showed Syk was expressed in normal 
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breast tissues, but was low or lost at the protein and mRNA level in breast carcinomas 
(22). This was expanded upon by Yuan who observed hypermethylation at the CpG 
island of the Syk promoter in 30% of breast cancer cell lines, suggesting Syk silencing 
through epigenetic modification, also by the Meuller group who, with siRNA and shRNA 
knockdown of Syk, showed increased growth, proliferation, motility, and invasiveness in 
normal MCF10A breast epithelial cells (30,31). Similar cases were seen in gastric 
carcinoma, where 21 out of 61 cases of gastric carcinoma showed SYK hypermethylation 
at its promoter, with subsequent reduced Syk mRNA and protein levels (26). Further 
studies utilizing ectopic expression of Syk in Syk negative metastatic breast cancer cell 
line MDA-MB-435BAG demonstrated that cells not expressing Syk were able to form 
invasive colonies in Matrigel, where Syk expressing cells were unable to form similar 
colonies and maintained their non-invasive spherical appearance (26). Hoeller et al. 
demonstrated similar results in a melanoma mouse model (32). In their study, metastatic 
melanoma cell lines expressing control or exogenous Syk were injected into the tail vein 
of mice. After 40 days, mice without Syk expressed up to 70 metastatic lesions in 10/12 
mice (32). In contrast, mice injected with Juso-Syk cells formed less than three metastatic 
lesions in 8 out of 12 mice, suggesting Syk’s role in cancer invasiveness (32).  
 
1.3 Syk signaling in Cancer Cell Motility 
 The ability of a cancer cell to gain motility has been associated with metastases 
and lower survival rate. Reactivation of Syk in highly metastatic breast carcinomas 
reduced cell motility in vitro, suggesting Syk may play a critical role in cancer 
invasiveness and progression (33). Studies utilizing MCF7 breast carcinoma cells 
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expressing exogenous Syk with an enhanced green fluorescent protein tag (Syk-EGFP) 
enhanced the localization of vinculin, a cytoskeletal protein associated with cell-cell and 
cell-matrix junction, to cell-cell junctions promoting cell-cell adhesion (34). Cortactin, 
found in E-cadherin adhesion assemblies, was also shown to be relocated to sites of cell-
cell contact within Syk-expressing MCF7 cells (34). Further studies demonstrated that 
over-expression of Syk in highly invasive MDA-MB-231 breast cancer cells reduced 
motility through inhibition of the phosphatidylinositol 3’kinase (PI3K) and subsequent 
down-regulation of the nuclear factor kappa-light-chain-enhancer of activated B cells 
(NFκB) transactivation (35). NFκB promotes activation of matrix metalloproteinases 
through urokinase-type plasminogen (uPA) (35). This suggested that Syk expression 
leads to down-regulation of the NFκB followed by reduction in uPA and cell motility 
(35). Reduced expression of Syk by piceatannol, a Syk inhibitor, in MCF7 cells enhanced 
the NFκB activity, uPA secretion, and cell motility (35).  
 Interestingly, recent studies by Singh et al. suggested an association between Syk 
expression and the expression of epithelial to mesenchymal transition (EMT) markers 
(36). EMT is a process in which epithelial cells lose their polarity and intercellular 
adhesion (37). This is associated with loss of epithelial markers, such as E-cadherin, and 
gain of mesenchymal markers, such as N-cadherin, vimentin, and a motile phenotype  
(37).  Singh et al. demonstrated that loss of Syk expression in multiple K-Ras dependent 
carcinomas was associated with a loss of E-cadherin, indicative of EMT (36). This 
finding, along with previously mentioned association between Syk and cortactin, give a 
strong indication loss of Syk and a subsequent gain in cancer cells motility could be 
through EMT.  
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1.4 Protein Arginine Methyltransferase  
 There are a total of nine Protein Arginine Methyltransferases (PRMT) encoded in 
the mammalian genome, all of which can catalyze the transfer of one or more methyl 
groups from S-adenosylmethionine (SAM) to the terminal nitrogen atoms of the 
gaunidino group of an arginine residue (38,39). The nine methyltransferases can be 
classified into three distinct groups: Type 1, ω-NG, NG- asymmetric dimethylarginine 
(ADMA); Type 2, ω-NG, NG-symmetric dimethyarginine (SDMA); and Type 3, ω-NG-
monomethylarginine (MMA) (39) (Figure 1.2). Type I includes PRMT1, PRMT2, 
PRMT3, CARM1, and PRMT8. PRMT5 and PRMT7 are the only type II and type III 
protein arginine methyltransferases, respectively. PRMT9 has yet to be classified (39). 
These PRMTs are associated with signal transduction, gene transcription, DNA repair, 
mRNA splicing, and have been linked to carcinogenesis and metastasis (39). For the 
purpose of this research, attention will be given to PRMT5 and PRMT7 and their 
association with cancer metastasis.  
1.4.1 PRMT5 
As mentioned previously, PRMT5 is the only type II methyltransferase, indicating its 
ability to catalyze the symmetric addition of two methyl groups to the two terminal 
guanidino group of arginine (40). PRMT5 contains a N-terminal TIM barrel domain, 
followed by a Rossman fold domain, and a catalytic C-terminal β-barrel domain (40,41) 
(Figure 1.3). It exists in a homodimer, whose bulk interaction between monomers is  
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Figure 1.2 Schematic of Arginine Methylation by PRMT 
 
Methylation of the guanidino nitrogen atom of the target arginine residue by various 
protein arginine methyltranferases can yield three different methyl additions: 
monomethylation, symmetric dimethylation, or asymmetric dimethylation.  Their 
methylation function has been associated with gene transcription, DNA repair, mRNA 
splicing, and cancer cell progression and metastasis. As this figure displays, PRMT7 is 
the only type III PRMT, and PRMT5 is the only type II PRMT. 
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dependent on the Arg-Asp salt bridge formation between the TIM barrel and the 
Rossman fold (40,41). The SAM binding site can be found at the N-terminal linker region 
helix α-Y and the LO loop of the Rossman fold domain, creating a secluded, solvent-
shielded catalytic active site (40,42). The active site of PRMT5 is located on the hairpin 
loop, or “double-E loop,” that links β4 of the Rossman fold domain, and the αF of the β-
barrel (40). This double-E loop contains a pair of glutamates, which are conserved across 
all PRMT proteins and required for catalytic activity (42). These glutamates are 
potentially involved in deprotonating and activating the methyl-accepting nitrogen (42). 
The histone substrate binds to a groove on the surface of the β-barrel and forms 
substantial interactions between the backbone of the histone with the α-Y helix large loop 
linker region that connects the TIM-barrel to the Rossman fold (41,42). Upon binding, 
the arginine side-chain is then inserted into a narrow tunnel formed by Leu312, Phe327, 
and Trp579 where it gains access to the active site to be methylated (41). Interestingly, 
tyrosine phosphorylation at Y297, Y304, and Y307 of the linker region by an oncogenic 
mutant of the Janus Kinase (JAK) impaired methyltransferase activity (42,43). Y304 and 
Y307 directly interacted with the histone substrates, and this interaction is disrupted by 
phosphorylation (42). Phosphorylation at Y297 alters the electrostatics and geometry of 
PRMT5’s substrate binding site (42). This suggests phosphorylation as a mechanism to 











Figure 1.3 Schematic Diagram of PRMT5 
PRMT5 is made up of three domains, the TIM barrel, Rossman fold, and the β-barrel. For 
it to become catalytically active it must homodimerize. This is achieved through 
interactions between the TIM Barrel of one PRMT5 molecule and Rossman fold of the 
other. The SAM binding site is associated with the linker region between the TIM barrel 
and Rossman fold. The substrate binding is associated with the “double-E loop” that is 
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1.4.2 PRMT5 in Cancer 
 Increased PRMT5 expression levels have been observed in numerous carcinoma 
tissues including melanomas, breast, lung, ovarian, testicular, and prostate. Its 
overexpression has been associated with poor prognosis (44-49). Moreover, findings in 
prostate, testicular, and lung carcinomas suggest cellular localization of PRMT5 plays a 
role in progression of the disease state (49,50). In multiple prostate cancer cell lines, 
cytoplasmic PRMT5 enhanced the growth in a methyltransferase activity dependent 
manner, where nuclear localization inhibited cell growth in a methyltransferase activity-
independent manner (49). When PRMT5 is translocated to the cytoplasm it must form a 
complex with the androgen receptor interacting protein p44 in the cytoplasm in order for 
prostate cancer cell growth (49). Furthermore, Gu et al. demonstrated that PRMT5 is 
required for p44 translocation out of the nucleus, suggesting its critical role in prostate 
cancer cell growth (49). Similar results were also found in testicular cancer, where 
PRMT5 and p44 protein levels were enhanced in the cytoplasmic fractions of testicular 
tumor cells (48). Studies in both high-grade non-small-cell lung carcinoma (NSCLC) and 
pulmonary NET tumors were associated with higher cytoplasmic expression of PRMT5 
(48). Ibrahim et al. also demonstrated that cytoplasmic localization was associated with 
E-cadherin-low, vimentin-high NSCLC cell lines (46). This suggests a potential 
connection between PRMT5 and EMT driven metastasis of lung cancer (46). 
Unfortunately, PRMT5’s cytoplasmic signaling and role, in regards to cancer cell growth, 
have yet to be identified.  
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However, nuclear expression of PRMT5 has also displayed a potential role in 
cancer metastasis through the EMT process. In 2008, Hou et al. demonstrated PRMT5’s 
repressor role of the epithelial marking E-cadherin upon PRMT5’s translocation to the 
nucleus (51). This group showed that PRMT5 binds to the AJUBA family of LIM 
proteins, a corepressor for SNAIL, and the SNAIL transcription factor where it is then 
translocated into the nucleus. Once in the nucleus, SNAIL then anchors the 
PRMT5/AJUBA complex to E-cadherin’s promoter region where its methyltransferase 
activity is involved in transcriptional repression (51). Furthermore, the Wang group 
reported enhanced nuclear expression of PRMT5 in transformed B-cell lymphomas, as 
opposed to normal B cells, with its expression in the nucleus associated with PRMT5 
enrichment at the promoter regions of all retinoblastoma family of tumor suppressor 
genes and subsequent increased H3R8 and H3R3 symmetric dimethylation and 
transcriptional repression of these genes (52).  
 
1.4.3 PRMT7 
 PRMT7 is a type III protein arginine methyltransferase, which means it catalyzes 
the addition of a single methyl group from SAM to a target arginine residue (39,53). 
Uniquely, PRMT7 is much different than its other PRMT family members. Most PRMTs 
contain a single core domain that is required to homodimerize in order to become 
catalytically active (53,54). PRMT7, in contrast, has two-tandem core domains forming a 
single homedimer-like arrangement that is catalytically active (53) (Figure 1.4). 
Moreover, the Clarke group determined that only the N-terminal core domain is 
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catalytically active, as the C-terminal binding pocket was occupied by the E loop and 
motif I of the C-terminal Rossman fold, and its E loop was missing the catalytic 
dependent glutamate residues (53,55).  This unique single core domain catalytic activity 
may explain why PRMT7 catalyzes monomethylation of arginine residues (53). PRMT7 
binds SAM in a similar manner as other PRMT family proteins, with SAM interacting 
between the N-terminal α-helix and Rossmann fold (42,53). However, PRMT7 arginine 
binding pocket is narrower than that of other PRMT proteins (53). This potentially 
inhibits the monomethlyated arginine from entering the binding pocket due to steric 
hinderance further indicating a type III like catalytic activity.  
 
1.4.4 PRMT7 in Cancer 
 Little is known about the role PRMT7 plays in cancer. In 2008, Verbiest et al. 
demonstrated that knockdown of PRMT7 in DC-3F, DC-3F/9-OH-E resistant hamster 
cells and HeLa cells sensitized them to camptothecin, a topoisomerase 1 inhibitor used in 
treatment of lung, ovarian, and colon cancers (56). This study suggested that PRMT7 
modulated cellular sensitivity to camtothecin downstream of the TOP1-DNA cleavage 
complex, but the mechanism still needs further investigation (56). It was not until 2014 
that the Jun Lu et al. presented strong evidence of the role of PRMT7 in inducing 
epithelial-to-mesenchymal transition and subsequent metastasis in breast cancer (57). 
This group demonstrated PRMT7 expression was missing from normal breast epithelial 
MCF10A cells, compared to a higher expression of PRMT7 in highly metastatic MDA-
MB231, MDA-MB231HM, and MDA-MB-435 breast epithelial cells (57). Moreover,  





1.4 Schematic Diagram of PRMT7 
Similar to the rest of the PRMT family, PRMT7 has a core domain made up of the 
Rossman fold and β-barrel. However, PRMT7 is unique in that contains two tandem core 
components, and does not require dimerization to be catalytically active. Interestingly, 
the N-terminal core, seen in dark purple and blue, is catalytically active, as opposed to the 
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they also showed that PRMT7 expression was enhanced in estrogen receptor negative  
(ER-) breast carcinomas, as well as high-grade (II/III) breast carcinomas (57). Ectopic 
expression of PRMT7 in MCF10A cells displayed morphologic changes in which they 
lost their epithelial cell-to-cell adhesions, becoming more fibroblast like (57). This was 
partnered with a loss of E-cadherin and an increase in the mesenchymal markers N-
cadherin, vimetin, and fibronectin, both at the mRNA and protein levels (57). Also, these 
PRMT7-MCF10A cells showed more mobility and invasive ability than empty vector 
transfected MCF10A cells (57). Conversely, MDA-MB-231 cells with siRNA 
knockdown of PRMT7 showed an overall increase in E-cadherin and decrease in 
vimentin and fibronectin expression at the mRNA and protein levels (57). Unfortunately, 
the mechanism by which PRMT7 alters the expression of E-cadherin is not fully 
understood. Increased PRMT7 expression has been associated with symmetric 
dimethylation of the histone 4 argine 3 (H4R2me2s). However, given the unique structure 
of PRMT7 and its ability to only monomethylate arginine residues, there is still a lack of 
information demonstrating how it is inducing dimethylation (40,42,57).  
 
1.5 SUPT5H 
PRMT5 targets multiple nuclear and cytoplasmic proteins for methylation.  
Among these proteins is SUPT5H (spt5), a 121 kDa protein associated with the 
regulation of transcription elongation (58). SUPT5H, along with a second protein, 
SUPT4H (spt4), were originally isolated from S. Cerevisiae (59). Later, it was reported 
that SUPT5H and SUPT4H were actually in a complex together and that their association 
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was necessary for transcriptional regulation (59).  This was further validated by the 
Handa group through the isolation of a complex containing SUPT5H and SUPT4H from 
HeLa cells that caused RNA polymerase II pausing upon treatment with the transcription 
inhibitor 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRG) (60). They identified 
this transcription elongation complex as DRB sensitivity-inducing factor (DSIF) (60).  
The Handa group went on to demonstrate that SUPT5H was required for the binding of 
both SUPT5H and RNA polymerase II (61).  In support of the role SUPT5H and 
SUPT4H as negative regulators of transcription elongation, Yamaguchi et al. 
demonstrated by immunoprecipitation that the negative elongation factor (NELF) was 
associating with the DSIF/RNA polymerase II complex and pausing RNA polymerase II 
(62).  
However, the opposite may be true as well. Recent findings suggest that the DSIF 
complex may also play a promoter role in transcription elongation (62,63). These 
findings showed that phosphorylation by the P-TEFb protein kinase of the C-terminal 
domain (CTD) of RNA polymerase II and the C-terminal region (CTR) of SUPT5H led 
to the dissociation of NELF, which serves as a switch from a negative to a positive 
transcription role for DISF (64). Interestingly, the catalytic symmetric dimethylation of 
one or more arginine residues on SUPT5H demonstrated a potential regulatory role in 
altering the ability of SUPTH5 to either inhibit or promote transcription elongation by 
PRMT5 (65). Studies by Kwaka and colleagues indicated that symmetric dimethylation 
of SUPT5H occurred at arginine 698 and was associated with a decrease in the SUPTH5-
SUPT4H-RNA polymerase II interaction (65).  
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SUPT5H has been associated with class switch recombination in mature B cells 
(66).  Class switching is the ability of a mature B cell to change its isotype by altering its 
heavy chain constant region (67). This allows the B cell to switch from expressing IgM to 
IgG, IgA or IgE (68). However, the complete mechanism by which class switching 
occurs is still unknown. Recent findings demonstrated that class switching is induced by 
B cell specific activation induced cytidine deaminase (AID) (69). However, AID does not 
facilitate class switching alone and has been associated with SUPT5H at sites of RNA 
polymerase II stalling at switch regions of the Ig locus (66). Consistent with these 
findings, knockdown studies of SUPT5H displayed significant decreases in the ability of 
cells to undergo CSR (68). Interestingly, SUPT5H is not the only protein to form a 
complex with AID. The Petersen-Mahrt group was able to show that AID and SUPT5H 
were also associated with the RNA polymerase-associated factor (PAF; PAF1, LEO1, 
CTR9) complex, SUPT6H, and the facilitates chromatin transcription (FACT; SSPR1, 
SUPT16H) complex, providing further insight into the CSR process (68). 
 
1.6 Perspective 
Syk depletion in numerous carcinoma models has been correlated with increases 
in motility and invasiveness of cancer cells. However, Syk’s downstream signaling role 
in cancer motility has yet to be completely understood. Recent findings have shown Syk 
interaction with multiple cell-cell junction mediating proteins, with loss of these tight 
junctions associated with loss of Syk. Moreover, loss of Syk has been associated with the 
reduction of E-cadherin, a predominant marker of EMT.  These findings demonstrate a 
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potential mechanism for Syk and cancer cell invasiveness via regulation of the EMT 
process. Syk, PRMT5 and PRMT7 have shown potential roles in breast cancer metastasis 
through the EMT process. This correlation has driven me to investigate Syk’s potential 
interaction with PRMT5 and PRMT7 and the role it plays in regulating arginine 
methylation in breast cancer cells.  
In a preliminary study, I was able to show that Syk expression altered di-
symmetric arginine methylation in MDA-MB231, MCF7, and DG75 cells through 
western blot analysis. This lead to the hypothesis that Syk plays a role in PRMT family, 
specifically PRMT5, methylation activity. Furthermore, in our phosphoproteomics 
studies, PRMT7 was found to be potentially phosphorylated by Syk on Y24 or Y26. 
These tyrosines are conserved across all PRMT family proteins, however PRMT7 is the 
only methyltransferase with acidic amino acids surrounding the tyrosine. They are also 
located in a region crucial for SAM binding. These findings further enhanced my 















2.1 Plasmids and DNA constructs  
 
The Syk-EGFP constructs were created by a former laboratory member as 
described previously (70). The GFP-PRMT7 plasmid for mammalian expression was 
provided by Dr. Steven Clarke (University of California, Los Angeles).  
 
2.2 Cell Culture 
MDA-MB-231 cells were purchased from American Type Culture Collection 
(ATCC). Syk-deficient MCF7 cells were purchased from BD Biosciences.  MDA-MB-
231 and MCF7 cells with tetracycline-regulated Syk-EGFP expression were constructed 
using the T-Rex system (Invitrogen) as described previously (71). These cells were 
treated with 1 µg/ml tetracycline to induce Syk-EGFP expression. Nucleolin knockdown 
MDA-MD-231 cells were generated by stably infecting cells with shRNA specific for 
nucleolin as described previously (72). These cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM, Sigma Aldrich) containing 7.5% fetal bovine serum (FBS, 
Gibco), 100 IU/ml penicillin G (Sigma-Aldrich), and 100 µg/ml streptomycin (Sigma-
Aldrich).  
DG75 human B-lymphoma cells were purchased from ATCC. These cells were 
grown in Roswell Park Memorial Institute medium (RPMI 1640, Sigma-Aldrich) 
	   20 
containing 10% FBS, 100 IU/ml penicillin, 100 µg/ml streptomycin, 50 µM 2-
mercaptoethanol (Sigma-Aldrich), and 1 mM sodium pyruvate (Gibco). A stable Syk 
knockdown DG75 cell line was generated by infecting DG75 cells with a lentivirus 
expressing the shRNA sequence for Syk as described previously (64). These cells were 
isolated by puromycin selection at 1 µg/ml. DG75 cells were transiently transfected with 
GFP-PRMT7 through electroporation using the GenePulser (BioRad). 1 x 107 cells were 
harvested in log phase growth and resuspended in 500 µl RPMI 1640 medium. Cells were 
added to an electroporation cuvette followed by the addition of 20 µg of GFP-PRMT7 
plasmid and allowed to incubate for 5 min at room temperature. The cells were then 
electroporated under the following parameters: voltage, 250 V; capacitance, 975 µF; 
resistance, ∞ resistance; cuvette, 4 mm. Cells were then added to 10 ml of RPMI medium 
and allowed to recover for 48 h. 
 
2.3 Antibodies and Reagents  
 Antibodies against Syk were from Santa Cruz. Anti-nucleolin, anti-PRMT5, anti-
PRMT7 were purchased from Abcam, and anti-symmetric dimethylarginine was from 
Millipore. Antibodies against green fluorescent protein (anti-GFP) was from Santa Cruz 
and anti-glyceraldehyde-3-phosphate dehydrogenase (anti-GPDH) was from Ambion. 
Antibodies against SUPT5H and LEO1 were from Abcam and anti-phosphotyrosine (pY) 
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2.4 Western Blotting 
Cells were washed with PBS and lysed in a buffer containing 1% NP40, 10% 
glycerol, 50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride 
(PMSF), 10 µg/ml of both aprotinin and leupeptin, and 1 mM sodium orthovanadate 
(Na3VO4). Lysates were sheared via brief sonication and centrifuged at 18,000 X g for 10 
min to remove cell debris. Protein concentrations were measured using the BCA assay 
(Thermo Scientific). Samples were mixed at a 1:1 ratio with a protein solubilizing 
mixture containing 2.5% SDS, 2.5 mM ethylenediaminetetraacetic acid (EDTA), 25 mM 
Tris/HCl, pH 8.0, pyroninY, 25% sucrose and 20% 2-mercaptoethanol. The mixture was 
boiled for 10 min before loading on sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) gel. Samples were transferred from gel to polyvinylidene 
difluoride (PVDF) membrane utilizing a Biorad transfer apparatus in a transfer buffer 
containing 25 mM Tris-HCl, pH 8.3, 192 mM glycine, 20% methanol, and distilled water 
for 1 h at 1 amp. Membranes were blocked in a 1% NP-40/Tris-buffered saline (TBS) and 
5% goat serum and primary antibodies for one h or longer at 4° C. After incubation with 
the primary antibody, membranes were washed twice with 0.05% NP-40/TBS buffer for 
10 min and once with 0.5 M NaCl in TBS for 10 min. Membranes were then either 
incubated with goat anti-rabbit or anti-mouse horseradish peroxidase conjugated 
secondary antibodies at a dilution of 1:5000 or 1:2000, respectively, in 0.05% NP-
40/TBS buffer with 5% goat serum for 1 h. The membranes were washed following the 
same methods as described above. Enzyme-linked chemiluminescence (ECL) reagents 
(PerkinElmer) and X-ray film were utilized to detect the protein bands. The dilutions for 
the primary antibodies used were: Syk 1:5000, GAPDH 1:2000, symmetric 
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dimethylarginine 1:1000, PRMT5 1:1000, PRMT7 1:1000, phosphotyrosine 1:10000, 
SUPT5H 1:1000, and LEO1 1:1000.  
 
2.5 Immunoprecipitation Assays 
Cells were washed with PBS and lysed in a buffer containing 1% NP40, 10% 
glycerol, 50 mM Tris/HCl, 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride (PMSF), 
10 µg/ml of both aprotinin and leupeptin, and 1 mM sodium orthovanadate (Na3VO4). 
Lysates were sheared via brief sonication and centrifuged at 18,000 X g for 10 min to 
remove cell debris. Protein concentrations were measured using the BCA assay. Equal 
amounts of lysates were pre-cleared through the addition of either protein A-Sepharose or 
protein G-Sepharose (Santa Cruz) on a rotator at 4° C for 30 min. Either protein A-
Sepharose or protein G-Sepharose was conjugated with primary antibody for 1 h. The 
pre-cleared lysates were then incubated with the beads conjugated with primary antibody 
at 4° for 4 h. The protein bead mixture was washed 3 times with lysis buffer, followed by 
1 wash with 250 mM NaCl. Samples were mixed with protein solubilizing mixture and 
boiled 10 min before being loaded onto SDS-PAGE gel for separation. The 



















Syk has been studied extensively in hematopoietic cells, where it serves as a 
downstream signaling component of the immunoreceptor tyrosine-based activation motif 
(6,7,8,9). However, our understanding of its role outside of the hematopoietic system, 
especially its role in tumor progression, is still in its infancy. For multiple carcinomas 
such as breast, prostate, and cervical, Syk expression has been associated with a tumor 
suppressor role (22,26-29) where loss of Syk is associated with enhanced cancer 
proliferation, motility, and invasiveness (22,30-31).  
Through mass spectrometry analyses, we were able to identify multiple substrates 
that are phosphorylated in a Syk-dependent manner (73). One such protein was a 
methyltransferase enzyme, PRMT7, which belongs to a family of protein arginine 
methyltransferase enzymes (38,39). Interestingly, recent studies of both PRMT7 and its 
family member PRMT5 have demonstrated that they are overexpressed in carcinoma 
tissue such as breast cancer, and their overexpression and subsequent catalytic activity 
has been linked to the increased motility and invasiveness of these tumor cells (44-
49,51,56,57). These observations have led to the investigation of the potential role of Syk 
in the regulation of PRMT5 and PRMT7 methylation activity in cancer cell models. 
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3.2 Syk Alters Di-Symmetric Arginine Methylation 
I first wanted to determine if Syk could alter di-symmetric arginine methylation. 
Utilizing MDA-MB-231 cells, which are Syk deficient, and a line of tetracycline-
responsive MDA-MB-231 cells that inducibly express Syk-EGFP, I performed a western 
blot analysis to observe any potential change in arginine di-symmetric methylation. I 
treated the Tet-responsive Syk-EGFP cells with tetracycline for 48 hours before lysing. 
Cells were lysed with buffer containing 1% NP-40 and a protease inhibitor cocktail. 
Proteins were separated by SDS-PAGE and transferred to a PVDF membrane. Di-
symmetric methylation was probed using polyclonal antibodies against di-symmetrically 
methylated arginine. Syk-EGFP expression was verified using antibodies against Syk;  
antibodies against GAPDH were used as a measure of equal loading.  The western blot 
revealed a protein of 75 kDa whose methylation was increased in the Syk-EGFP-
expressing cells as compared to cells lacking Syk (Figure 3.1A). 
To determine if this Syk-dependent change was specific only to MDA-MB-231 
cells or could be observed in other cell types, I performed a similar experiment using a 
line of MCF7 breast cancer cells that lack Syk expression as compared to a Tet-
responsive line of MCF7 cells in which the expression of Syk-EGFP could be induced.  
Again, a band of approximately 75 kDa was preferentially observed in the lysates of Syk-
EGFP-expressing cells (Figure 3.1B).  To determine if the methylation could also be 
altered by the expression of Syk at normal endogenous levels, I compared human DG75 
B lymphoma cells, which normally express Syk with a line of DG75 cells in which the 
expression of Syk was reduced by expression of an shRNA directed against the Syk 
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message. Again, the 75 kDa dimethylated protein was observed preferentially in the cells 
expressing the higher levels of Syk (Figure 3.1C).    
 
3.3 Interaction Between Syk and PRMT5 
PRMT5 is the only arginine methyltransferase that catalyzes the symmetric 
dimethylation of the terminal nitrogen atom of the guanidino group of arginine (38,39).  
A previous mass spectrometric analysis of Syk-dependent substrates identified CLNS1A 
a component of a methylosome complex that contains PRMT5 (74,75).  This suggested 
that Syk interacts with CLNS1A and, potentially, PRMT5. To determine if Syk could 
associate with PRMT5, I used Syk deficient MDA-MB-231 and Tet responsive Syk-
EGFP-expressing MDA-MB-231 cells for co-immunoprecipitation assays. Cells were 
treated for 48 hour to induce the expression of Syk-EGFP. Both the Syk-deficient and 
Syk-EGFP-expressing MDA-MB-231 cells were lysed. Syk-EGFP was 
immunoprecipitated utilizing GFP-nanotrap beads, which bind tightly to the EGFP tag.  
Cell lystates and the immune complexes were separated by SDS-PAGE and analyzed by 
western blotting using antibodies against Syk and PRMT5. Interestingly, the western blot 
analysis showed that PRMT5 was indeed present in the Syk-EGFP immune complex, 
confirming that Syk and PRMT5 do, in fact, associate with one another (Figure 3.2).  
 
3.4 Nucleolin Dependent Syk-PRMT5 Interaction  
 In 2007, the Bates group examined proteins associated with nucleolin (76). 
Nucleolin is a multifunctional protein that is involved in transcription regulation, cell 
growth and proliferation (77-80). Through immunoprecipitation and mass spectrometry 
	   26 
analysis, the Bates group demonstrated that PRMT5 interacts with nucleolin (76). This 
was further verified by studies performed by the Grimmler group who showed that 
PRMT5 was recruited to nucleolin via RioK1 (81). Recent research in our laboratory has 
demonstrated that Syk also interacts with nucleolin (72). Based on these findings, I 
decided to determine if nucleolin played a functional role in the PRMT5-Syk interaction.  
Syk deficient MDA-MB-231, Tet-responsive Syk-EGFP-expressing MDA-MB-231, and 
Tet-responsive Syk-EGFP-expressing MDA-MB-231 cells expressing shRNA for 
nucleolin were induced with tetracycline to express Syk-EGFP.  Syk-EGFP-MDA-MB-
231 cells containing the shRNA sequence for nucleolin were selected with puromycin 
treatment. After 48 hours of tetracycline treatment, cells were lysed and Syk-EGFP was 
immunoprecipitated with GFP-nanotrap beads. Whole cell lystates and immune 
complexes were separated by SDS-PAGE and proteins were visualized by western blot 
analysis using antibodies against Syk, nucleolin, PRMT5 and GAPDH.  An analysis of 
proteins present in the resulting immune complex confirmed a nucleolin-dependent 
interaction between Syk and PRMT5, with knockdown of nucleolin associated with a 
decrease in the presence of PRMT5 in the immune complex (Figure 3.3).  
 
 
3.5 Syk’s Interaction with PRMT5’s Substrate SUPT5H 
 
 Since my experiments suggested that Syk was present in a complex that contained 
PRMT5, I examined these complexes for the presence of other potential Syk and PRMT5 
substrates.  Previous work in our lab, in collaboration with the Tao lab, identified via a 
mass spectrometry-based phosphoproteomic screen a large library of proteins that are 
potentially phosphorylated in a Syk-dependent manner (73). Comparing the database  






Figure 3.1: Symmetric Arginine Dimethylation is Altered in a Syk-Dependent Manner in 
MDA-MB-231, MCF7 and DG75 cells  
 
 
Western blot anaylsis utilizing antibodies against symmetric arginine dimethylation was 
performed on (A) MDA-MB-231 cells lacking or induced to express Syk-EGFP lysates, 
(B) MCF7 lysates lacking or inducing expression of Syk-EGFP, (C) DG75 and Syk 









Figure 3.2: Interaction Between Syk and PRMT5  
 
 
Syk-EGFP was immunoprecipitated utilizing GFP-nanotrap beads from lysates of MDA-
MB-231 cells either lacking or expressing Syk-EGFP. The lysates and immune 
complexes were separated by SDS-PAGE and analyzed by western blot using antibodies 


















Figure 3.3: Nucleolin-Dependent Interaction Between PRMT5 and Syk 
 
 
MDA-MB-231 and MDA-MB-231 cells in which nucleolin levels were knocked down 
with shRNA were treated with tetracycline to induce EGFP-Syk expression and lysed 48 
hours after treatment. Syk-EGFP was immunoprecipitated from cell lysates by GFP-
nanotrap beads. Whole cell lystates and immune complexes were separated by SDS-
PAGE and probed by western blot using antibodies against Syk, PRMT5, and nucleolin. 
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with current literature, I was able to identify the SUPT5H transcription elongation factor 
as both a target of PRMT5 methylation and Syk phosphorylation (65). SUPT5H is a 
component of the DRB-sensitivity-inducing factor. Upon phosphorylation or methylation, 
SUPT5H stimulates or inhibits transcriptional elongation respectively (63,65,82). 
Utilizing Syk-deficient MDA-MB-231 and MCF7 cells, along with Tet-responsive Syk-
EGFP-expressing MB-MDA-231 and Syk-EGFP-expressing MCF7 cells, I investigated 
Syk’s potential to interact with SUPT5H. SUPT5H was immunoprecipitated using 
antibodies against SUPT5H from lysates of cells lacking Syk and cells expressing the 
EGFP tagged Syk after treating cells with 5 mM H2O2 for 10 minutes (conditions that 
lead to the activation of Syk). Whole cell lysates and immune complexes were separated 
by SDS-PAGE and probed for SUPT5H, Syk, and GAPDH via western blot analysis. Syk 
appeared in the SUPT5H immune complex in both MB-MDA-231 and MCF7 cells 
expressing Syk-EGFP, suggesting an interaction between Syk and SUPT5H (Figure 3.4 
A, B). To determine if Syk was phosphorylating SUPT5H, I stripped and re-probed the 
western blot of MCF7 cells lacking or expressing EGFP-Syk with or without H2O2 
treatment with antibodies against phosphotyrosine. The western blot analysis suggested 
that SUPT5H phosphorylation was enhanced with cells expressing EGFP-Syk (Figure 3.4 
B).  
 I also wanted to examine the potential effects Syk expression might have on the 
interaction between PRMT5 and SUPT5H. MDA-MB-231 cells deficient in Syk 
expression or treated with tetracycline to induce Syk-EGFP were lysed and used in an 
immunoprecipitation assay using antibodies against SUPT5H. The immune complex was 
separated by SDS-PAGE and proteins were visualized using western blot with antibodies 
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against Syk, PRMT5 and SUPT5H. PRMT5 was found in both immune complexes from 
cells lacking Syk or expressing Syk-EGFP (Figure 3.5).  Thus, Syk is not required for the 
interaction between PRMT5 and SUPT5H. 
 
3.6 Interaction between Syk and LEO1 
 Recent findings have shown that SUPT5H associates with the activation induced 
cytidine deaminase and RNA polymerase-associated factor 1 complexes where it plays a 
role in class switch recombination in mature B cells (68). Interestingly, we found that a 
component of the PAF1 complex, LEO1, also was a protein in our library of substrates 
phosphorylated in a Syk-dependent manner (73, 83). To validate a Syk interaction with 
LEO1, I immunoprecipitated Syk-EGFP with GFP-nanotrap beads or LEO1 with beads 
conjugated with antibodies against LEO1 from lysates of Syk deficient MDA-MB-231 
and Syk-expressing MDA-MB-231 cells. The lysates and immune complexes were 
separated by SDS-PAGE and analyzed by western blotting with antibodies against Syk or 
LEO1. LEO1 was coimmunprecipitated with Syk-EGFP and Syk-EGFP 
coimmunoprecipitated with LEO1, confirming an association between the two proteins 
(Figure 3.6 A, B).   
 
3.7 Syk is Part of the SUPT5H, LEO1 Complex but is not Required for its Formation 
 To determine if SUPT5H and LEO1 were interacting with each other in a Syk-dependent 
manner, I treated MDA-MB-231 cells lacking or expressing Syk-EGFP with or without 
hydrogen peroxide to activate Syk. Then, I immunoprecipitated either SUPT5H or LEO1 
using antibodies against these proteins. 
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Figure 3.4: Syk Interacts with SUPT5H in MDA-MB-231 and MCF7 Cells  
 
 
(A) Syk deficient and tetracycline induced Syk-EGFP-expressing MDA-MB-231 cells 
were lysed in 1% NP-40 lysis buffer. Cell lysates were subject to immunoprecipitation 
using antibodies against SUPT5H. Lysates and immune complexes were separated by 
SDS-PAGE and analyzed by western blot with antibodies against Syk and SUPT5H. 
GAPDH was used as a loading control. A mock IP (m) with beads not conjugated to an 
antibody were used as a control for non-specific binding. Cells were treated with 5 mM 
H2O2 for 10 minutes where indicated. (B) SUPT5H was immunoprecipitated from lysates 
of MCF7 cells lacking Syk or induced to express Syk-EGFP using antibodies against 
SUPT5H. The lysates and the immune complexes were analyzed by western blot utilizing 
antibodies against Syk, SUPT5H and phosphotyrosine. Cells were treated with 5 mM 
H2O2 for 10 minutes where indicated. The migration position of Syk is indicated by the 
white arrows.  







Figure 3.5: PRMT5 Interacts with SUPT5H Independent of Syk Expression  
 
 
SUPT5H was immunoprecipitated from lysates of MDA-MB-231 cells lacking Syk or 
expressing Syk-EGFP using antibodies against SUPT5H. The immune complex was 
separated by SDS-PAGE and proteins were visualized by western blot utilizing 
antibodies against SUT5H, Syk and PRMT5. A mock IP (m) with beads not conjugated 
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Figure 3.6: Syk Interacts with LEO1 in MDA-MB-231 Cells  
 
 
(A) MDA-MB-231 cells lacking Syk or expressing Syk-EGFP were lysed.  Syk-EGFP 
was immunoprecipitated from the cell lysate using GFP-nanotrap beads. The immune 
complexes and lysates were separated on SDS-PAGE and analyzed by western blot with 
antibodies against LEO1, Syk, and GAPDH. (B) Syk deficient MDA-MB-231 cells 
MDA-MB-231 cells induced to express Syk-EGFP with tetracycline were lysed.  LEO1 
was immunoprecipitated from the lysates using antibodies against LEO1. Lysates and the 
immune complexes were separated by SDS-PAGE and proteins were visualized by 
western blot analysis using antibodies against LEO1, Syk and GAPDH. A mock IP (m) 
was used as a control for nonspecific binding.  
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Cell lysates and immune complexes were separated by SDS-PAGE and western blots 
were analyzed for SUPT5H, LEO1, and Syk. GAPDH was used as a loading control. 
Indeed, both SUPT5H and LEO1 associated with each other in either MDA-MB-231cells 
lacking or expressing Syk-EGFP. This indicates that their association is independent of 
Syk and its ability to phosphorylate SUPT5H. Syk was still coimmunoprecipitated in 
both assays, suggesting it may still play a functional role within this complex (Figure 
3.7).    
 
3.8 PRMT7 is not Phosphorylated by Syk in DG75 Cells 
As previously mentioned, our phosphoproteomic mass spectrometry analysis 
demonstrated the potential phosphorylation of PRMT7 on tyrosines 24 and 26 (73). What 
is unique about these tyrosines is the fact that they are conserved across all of the PRMT 
proteins. However, PRMT7 is the only methyltransferase in the group whose tyrosines 
are located in a region surrounded by acidic residues, EEDEHYDY. This is interesting as 
Syk preferentially targets tyrosines in acidic regions for phosphorylation (84). Moreover, 
Y24 and Y26 are located within the N-terminal region where SAM binding occurs. In an 
attempt to confirm Syk’s ability to interact with and phosphorylate PRMT7, I used DG75 
cells and DG75 cells where Syk levels were reduced by shRNA expression.  Both cell 
types were transiently transfected with PRMT7-GFP. 48 hours after transfection, cells 
were lysed in 1% NP40 lysis buffer and PRMT7-GFP was immunoprecipitated from cell 
lysates by incubating lysates with GFP-Trap beads. The immuncomplexes were analyzed 
by western blotting using antibodies against GFP, Syk and phosphotyrosine. Western 
blotting with antibodies against GFP confirmed transfection. However, neither Syk nor 
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phosphotyrosine appeared in the immune complex suggesting that PRMT7 is not a target 
for Syk-catalyzed phosphorylation in DG75 cells (Figure 3.8). This also suggests that Syk 
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Figure 3.7: Interaction Between SUPT5H and LEO1 is Independent of Syk Expression  
 
 
(A) MDA-MB-231 cells lacking or expressing Syk-EGFP were treated with 5 mM H2O2 
for 10 minutes and then lysed in 1% NP-40 lysis buffer. SUPT5H was 
immunoprecipitated from cell lysates using antibodies against SUPT5H conjugated to 
protein A Sepharose beads. Lysates and immune complexes were separated by SDS-
PAGE and analyzed by western blot using antibodies against SUPT4H, LEO1 and Syk. 
GAPDH was used as a loading control. A mock IP (m) was used as a control for 
nonspecific binding. (B) Syk deficient or tetracycline induced Syk-EGFP expressing 
MDA-MB-231 cells were lysed and LEO1 was immunoprecipitated from whole cell 
lysates. Lysates and immune complexes were separated by SDS-PAGE and proteins were 
visualized by western blot utilizing antibodies against LEO1, SUPT5H, Syk and 
















Figure 3.8: Syk does not Interact with PRMT7-GFP 
 
 
DG75 and DG75 Syk shRNA knockdown cells were transiently transfected with a 
PRMT7-GFP vector. 48 hours after transfection, cells were treated with 5 mM H2O2 and 
then lysed in buffer containing 1% NP-40. GFP-nanotrap beads were used to 
immunoprecipitate GFP tagged PRMT7 from cell lysates. Lysates and immune 
complexes were separated by SDS-PAGE and probed for protein expression through 
western blotting using antibodies against GFP, Syk, phosphotyrosine, and GAPDH. 
DG75 and DG75 Syk knockdown cells not transfected with vector were used as a 




















4.1 Introduction  
 
Syk kinase expression extends across a multitude of cell types. It has been 
extensively studied in hematopoietic cells where it plays a critical role in downstream 
signaling of immune receptors. This downstream signaling is essential for cell processes 
such as B-cell activation and development (85-87). Moreover, in hematopoietic cancers 
such as B-cell acute lymphocyte leukemia, non-Hodgkins lymphoma and small 
lymphocytic leukemia/chronic lymphocytic leukemia, Syk expression and signaling are 
associated with a tumor promoter role (23-25). This is thought to be due to tonic 
signaling from the B cell receptor for antigen (88).  However, the function of Syk when 
expressed outside of hematopoietic tissues requires further investigation. Recent findings 
demonstrate that Syk expression is associated with a tumor suppressor role in some 
epithelial-based carcinomas such as breast, gastric, cervical, and hepatocellular (22,26-
29). In particular, loss of Syk expression both at the mRNA and protein level via 
hypermethylation of its promoter is associated with poor prognosis and increased 
invasiveness of breast and gastric cancers (22,26,30,31).  
Investigations into the mechanisms by which loss of Syk in these epithelial-based 
carcinomas leads to their increased metastatic characteristics have suggested a role in for 
the kinase in epithelial-to-mesenchymal transition, a process by which cells lose polarity 
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and cell-cell adhesions  (36). This mechanism is supported by recent findings that Syk 
associates with multiple cytoskeletal proteins that promote cell-cell adhesion (34). 
Furthermore, the knockdown of Syk expression in breast cancer cells is associated with a 
loss of E-cadherin, a significant marker of EMT (37). this was also true for the K-Ras-
addicted pancreatic carcinomas (36). The association of Syk with this cellular mechanism 
provides an interesting area of investigation, as the cellular signaling associated with Syk 
and its connection with EMT has yet to be fully explored.  
This led to our investigation of Syk and its signaling in cancer cell models. My 
focus in this study was to examine Syk’s role in regulating symmetric arginine di-
methylation, as well as exploring Syk’s ability to interact with the methyltransferase 
enzymes PRMT5, which catalyzes symmetric dimethylation, and PRMT7, which 
catalyzes monomethylation. The vested interest in these methyltransferase enzymes stems 
from the observations that their overexpression in multiple cancer models is associated 
with a loss of E-cadherin and enhanced vimentin and N-cadherin expression, which are 
all known EMT markers (44-49,51,57).   
 
4.2 Syk Alters Symmetric Dimethylation of Arginine and Interacts With PRMT5 
Our preliminary studies indicated that Syk expression in DG75, MCF7, and 
MDA-MB-231 cells is associated with an increase in the symmetric dimethylation of a 75 
kDa protein (Figure 3.1). Previous investigations of methyltransferases demonstrated that 
only PRMT5 of the PRMT family of proteins is able to catalyze the symmetric addition 
of two methyl groups onto the terminal nitrogen atom of the guanidino group of arginine 
(38,39). My studies demonstrate that Syk and PRMT5 interact with one another, 
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providing some rationale as to how Syk expression might be regulating symmetric 
dimethylation of a 75 kDa protein (Figure 3.2).  
My results also demonstrated that, in MDA-MB-231 cells, the interaction between 
Syk and PRMT5 is dependent on nucleolin. This is in agreement with our prior report 
demonstrating Syk’s interaction with nucleolin (72) and other reports of PRMT5’s 
interaction with and methylation of nucleolin (76,81). Our findings are interesting as the 
interaction between PRMT5 and nucleolin is associated with changes in cellular 
localization of the complex. Moreover, the cellular localization of PRMT5 plays a role in 
tumor progression and prognosis (49). Teng et al. demonstrated a nucleolin mediated 
nuclear-to-cytoplasmic redistribution of PRMT5 upon treatment with the oligonucleotide 
aptamer AS1411, a ligand for nucleolin (76). The Grimmler group followed this 
discovery with findings that suggested that RioK1, an exclusively cytoplasmic protein, 
directs nucleolin to PRMT5 (81).  My attempts to demonstrate an effect of Syk 
expression on PRMT5’s relocation either into or out of the nucleus through 
immunofluorescence were unsuccessful (data not shown) as PRMT5 was evenly 
distributed between the cytoplasm and nucleus and this did not appear to change as a 
function of the presence or absence of Syk. However, this is not to say that under certain 
stimulation conditions, such as treatment with AS1411, Syk would not have had an effect 
on the localization of this complex.  
It would be interesting to identify the 75 kDa substrate whose enhanced 
symmetric di-methylation was Syk dependent. A reasonable method for determining this 
protein’s identity would be by immunoprecipitation and mass spectrometry (89). Proteins 
that were symmetrically di-methylated could be immunoprecipitated out of cell lysates 
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utilizing antibodies against symmetric dimethylarginine conjugated to protein A 
sepharose beads. These proteins could then be digested by endoproteinases such as 
trypsin. The peptides could then be analyzed by mass spectrometry (65). Using Proteome 
Discoverer provided by thermo Fisher Scientific, mass spectrometry results could be 
compared against a Homo sapiens database to identify the symmetrically dimethylated 
substrates, including the 75 kDa protein of interest (73).  
 
4.3 Syk’s Interaction with SUPT5H, a Substrate of PRMT5 
 Previous investigations have demonstrated that PRMT5 forms complexes with 
various proteins, such as CLNS1A and Sm proteins to regulate gene splicing or with 
PDCD4 to enhance tumor cell growth (45,75,90). My western blot and 
immunoprecipitation assays further support this idea, as I could show that PRMT5 forms 
a complex with both Syk and nucleolin.  My investigation expanded upon the complex 
formation between Syk and PRMT5 with my finding that PRMT5 and Syk form a 
complex with SUPT5H (Figure 3.4, 3.5). Using MD-MBA-231 cells, I also demonstrated 
Syk’s ability to interact with LEO1, a protein shown to be associated with SUPT5H in a 
multi-protein complex that regulates class switch recombination in mature B cells (68).  
 My findings suggest that Syk is part of this complex, but is not required for the 
SUPT5H and LEO1 interaction (Figure 3.6). Although no direct link between SUPT5H 
or LEO1 expression or function in tumor development and progression has been 
discovered, it is still an interesting finding as this suggests a potential new role for Syk in 
later stages of B cell development. As previously mentioned, SUPT5H and LEO1 are 
components of a larger complex containing the fact complex, PAF complex, SUPT4H, 
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AID and SUPT6H, which regulate the ability of a mature B cell to undergo isotype 
switching resulting from IgM to IgA or IgE (67,82).  
Further work would be necessary to formally demonstrate a role for Syk in class 
switch recombination. The Honjo group developed an in vitro class switching system in 
which CH12F3, a subclone of the CH12.LX lymphoma cell, can be induced to switch 
surface IgM to IgA (91). In this system, cells expressing surface IgM are treated with IL-
4, transforming growth factor beta (TGF-β), and CD40L for 72 hours to induce class 
switching (91). Class switch recombination could then be assessed utilizing flow 
cytometry by staining the surface Ig with antibodies against IgM and IgA (91,92). By 
treating these cells with a Syk inhibitor, such as piceatannol or R406, one could measure 
the direct effect Syk activity has on the mature B cell’s ability to undergo class switch 
recombination. Given previous studies demonstrating Syk’s expression is required for B 
cell development and maturation, its role in mature B cell class switch recombination 
would be an interesting cellular mechanism to investigate further.  
 
4.4 Syk Interaction with PRMT7 
PRMT7 overexpression is associated with highly invasive carcinomas (57). 
Moreover, its two N-terminal tyrosines determined in our Syk dependent 
phosphoproteomic mass spectrometry analysis and their unique placement within a 
region of acidic residues made it a protein of interest to examine for a potential Syk 
interaction (73,84). Difficulty in obtaining antibodies that were selective enough against 
PRMT7 led to my use of PRMT7-GFP. I transfected the GFP tagged PRMT7 into  DG75 
and DG75 Syk shRNA knockdown Burkitt’s lymphoma cells, as these cells express 
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endogenous Syk and are fairly easy to transfect. Although the transfection was 
successful, I was unable to detect a Syk interaction, or a Syk-dependent phosphorylation 
of the PRMT7-GFP (Figure 3.7). This may indicate that Syk interacts with PRMT5, but 
not PRMT7. However, one cannot rule out that the possibility that the GFP tag may be 
causing steric interference at the site where Syk interacts with PRMT7.  The site of 
tyrosine phosphorylation on PRMT7 is, in fact, located near the N-terminus of the 
protein. 
A reasonable alternative to transiently transfecting cells with PRMT7-GFP would 
be to use an in vitro protein kinase assay to confirm the ability of Syk to phosphorylate 
PRMT7.  Utilizing a GST-PRMT7 bacterial expressing plasmid that can be obtained 
from Addgene and His6-Syk, I could express and ability to purify these proteins from 
bacteria and HEK293T cells, respectively. Both GST-PRMT7 and His6--Syk could then 
be incubated together with the addition of [γ-32P]ATP.  Phosphorylation by Syk could be 
detected by autoradiography. Given that the sites of potential Syk phosphorylation are in 
the region where SAM binds, this protein kinase assay could also be useful in measuring 
Syk’s effect on PRMT7’s catalytic activity. By incubating GST-PRMT7 and His6-Syk in 
a buffer containing a peptide sequence that resembles a substrate of PRMT7 and 
[14C]AdoMet, the methylated products could be isolated by P81 filter paper and 
quantified using a scintillation counter.  
 
4.5 Conclusions 
In summary, I have shown that Syk alters symmetric dimethylation of a protein 
that is roughly 75 kDa. Using breast cancer cell models, Syk was found to interact with 
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PRMT5, which is the only known methyltransferase shown to catalyze the symmetric 
addition of two methyl groups to an arginine residue. Interestingly, this interaction is 
dependent on the presence of nucleolin. The interaction between PRMT5 and Syk 
provides preliminary evidence on a mechanism by which Syk expression could alter 
symmetric dimethylation. Further investigation of this mechanism, as well as the 75 kDa 
protein whose methylation is altered by Syk expression, is required.  
Through examination of substrates of both PRMT5 and Syk, I was able to 
demonstrate Syk’s ability to form a complex with SUPT5H and LEO1 proteins. These 
preliminary findings suggest a new, additional role that Syk plays in B cell development 
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